Skip to main content

Table 3 Crude and adjusted regression analysis of diagnostic time up to 12 months and independent variables in patients with rheumatoid arthritis in Blumenau, Santa Catarina, Brazil, 2014

From: Prevalence and factors associated with diagnosis of early rheumatoid arthritis in the south of Brazil

Variables

Crude analysis

Adjusted analysis

 

(RPc)

CI 95%

p

(PRa)

CI 95%

p

Sex (n = 296)

0,704*

  

0,720**

 Male

1,08

(0,7-1,6)

 

1,07

(0,7-1,6)

 

 Female

1

  

1

  

Age in years (n = 287)

  

0,894*

  

0,920**

 20–39

1

  

1

  

 40–59

0,91

(0,4-1,7)

 

0,91

(0,6-1,7)

 

  ≥ 60

0,96

(0,4-1,8)

 

0,95

(0,4-1,8)

 

Education in completed years (n = 284)

0,094

  

0,041

 0–4

1,37

(0,9-2,1)

 

1,59

(1,1 - 2, 5)

 

 5–8

1,20

(0,7-1,8)

 

1,29

(0,7-2,1)

 

  > 9

1

  

1

  

Current monthly personal income in minimum wages (n = 248)

0,496*

  

0,741**

 Third tertile (higher)

1

  

1

  

 Second tertile

0,96

(0,6-1,4)

 

0,91

(0,5-1,4)

 

 First tertile (lower)

1,11

(0,7-1,6)

 

1,07

(0,7-1,6)

 

Body mass index (Kg/m2) (n = 285)

0,001

  

0,001

  ≤ 24,9

1

  

1

  

 25–29,9

1,55

(1,0-2,3)

 

1,62

(1,0-2,4)

 

  ≥ 30

1,97

(1,2-2,9)

 

2,07

(1, 3 - 3,1)

 

Type of servicee in the last 12 months (n = 269)

0,515*

  

0,997**

 Public healthcare system

0,86

(0,5-1,3)

 

1,01

(0,6-1,6)

 

 Supplementary healthcare system

0,97

(0,6-1,4)

 

0,90

(0,5-1,4)

 

 Fee-for-service care

1

  

1

  

Total number of consultations with a rheumatologist in the last 12 months (n = 281)

0,074

  

0,223**

 0–1

0,75

(0,4-1,2)

 

0,79

(0,4-1,3)

 

 2–3

1

  

1

  

  ≥ 4

0,72

(0,5-1,0)

 

0,79

(0,5-1,1)

 

Disease time in months (n = 235)

0,134

  

0,115**

 0–24

1

  

1

  

  > 24

1,57

(0,8-2,8)

 

1,76

(0,8-3,5)

 

Use of csDMARD (n = 296)

0,994*

  

0,744**

 Yes

1

  

1

  

 No

0,99

(0,7-1,3)

 

1,08

(0,6-1,7)

 

Use of TNFi (ADA + ETA+IFX) (n = 288)

0,588*

  

0,217**

 Yes

0,91

(0,6-1,2)

 

0,75

(0,4-1,1)

 

 No

1

  

1

  

HAQ (n = 165)

0,227*

  

0,867**

 0–1 (mild)

1

  

1

  

 1,1–2 (moderate)

0,68

(0,4-1,1)

 

0,78

(0,6-1,1)

 

 2,1–3 (severe)

0,76

(0,4-1,2)

 

0,82

(0,6-1,3)

 

Presence of radiological changes (erosions) in hands (n = 237)

0,668*

  

0,877**

 No

1

  

1

  

 Yes

1,08

(0,7-1,5)

 

1,03

(0,6-1,6)

 

Current professional situation (237)

0,125

  

0,088**

 Working

1

  

1

  

 Health insurance

1,11

(0,6-1,8)

 

1,34

(0,8 – 2,1)

 

 Disability retirement

0,99

(0,6-1,4)

 

0,85

(0,5 – 1,3)

 

 Retirement for time of service

0,67

(0,4-1,1)

 

0,68

(0,4 – 1,1)

 
  1. csDMARD conventional synthetic disease-modifying antirheumatic drugs, TNFi tumor necrosis factor inhibitors, ADA adalimumab, ETA etanercept, IFX infliximab, HAQ health assessment questionnaire, PRc crude prevalence ratio; PRa: adjusted prevalence ratio; CI 95%: confidence interval of 95%
  2. * Value of p > 0,20 excluded from the adjusted analysis. ** Value of p > 0,05 excluded of final model